Burning Rock Biotech (NASDAQ:BNR) Director Buys $5,466,143.20 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 314,870 shares of Burning Rock Biotech stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the completion of the purchase, the director owned 17,672,676 shares in the company, valued at $306,797,655.36. This trade represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Burning Rock Biotech Trading Up 0.8%

BNR stock traded up $0.14 during trading on Thursday, reaching $16.44. 22,992 shares of the stock were exchanged, compared to its average volume of 28,586. The firm’s 50 day moving average is $26.13 and its 200 day moving average is $19.41. The firm has a market cap of $176.86 million, a P/E ratio of -20.80 and a beta of 1.35. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $2.18 and a twelve month high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $18.05 million during the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%.

Wall Street Analyst Weigh In

Several research firms have weighed in on BNR. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Burning Rock Biotech presently has an average rating of “Sell”.

Hedge Funds Weigh In On Burning Rock Biotech

Several large investors have recently bought and sold shares of BNR. Crcm LP grew its stake in shares of Burning Rock Biotech by 121.8% in the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after acquiring an additional 269,851 shares in the last quarter. Prospera Financial Services Inc boosted its holdings in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares during the last quarter. Marshall Wace LLP bought a new stake in Burning Rock Biotech in the 4th quarter worth about $220,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Burning Rock Biotech in the 3rd quarter valued at about $26,000. 30.03% of the stock is currently owned by institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.